Berkshire Hathaway Inc (BRK.B) Up 0.47%; in a Downtrend Over Past 14 Days

Berkshire Hathaway Inc 4 Hour Price Update

Updated June 24, 2020 04:39 PM GMT (12:39 PM EST)

In the past four hours of today’s trading session, BRK.B’s price is down $-2.93 (-1.62%). For context, Berkshire Hathaway Inc’s peers in the in the Insurance industry are down -3.86% on average in this time, while the broader Financial Services sector is down by an average of -4.34%.

Berkshire Hathaway Inc Daily Price Recap

Berkshire Hathaway Inc came into today up 0.47% ($0.84) from the open of the day prior, marking the 2nd day in a row an upward move has occurred. The price move occurred on volume that was up 9.66% from the day prior, but down 32.71% from the same day the week before. Here is a daily price chart of Berkshire Hathaway Inc.

Berkshire Hathaway Inc Technical Analysis

Notably, the current price of Berkshire Hathaway Inc is sitting close to its 50 day moving averages; moving average crosses often indicate a change in momentum, so this may be worth keeping an eye on. Trend traders will want to observe that the strongest trend appears on the 14 day horizon; over that time period, price has been moving down. Or to view things another way, note that out of the past 30 days Berkshire Hathaway Inc’s price has gone up 16 them.

Overheard Around the Web

Over on StockTwits, here’s an example of what they’re saying about BRK.B:

    $AVAV $ACMR $TSLA $BRK.B This week I believe that an EU and Novavax’s $NVAX partnership will be announced soon $100 could be happen. EU to use $2.7 billion fund to buy promising COVID-19 vaccines .The EU Commission hinted that time is of the essence, that they must strike NOW, and that they have been in discussions with various pharmaceutical companies for several weeks. They agreed to fold France, Italy, Germany and The Netherlands Inclusive Vaccine Alliance into EU Commision and go forward as one unit! That is 27 member countries needing a contract now! It needs to be sealed before the weekend.
    Novavax’s acquisition of Praha Vaccines along with other associated assets for $167 million in May 2020 new vaccine manufacturing facility located in Bohumil, Czech Republic will develop and manufacture the company’s vaccine candidate for Covid-19, NVX‑CoV2373